Evidence map›Paper›PMID 41536780›Full record

Trial reportBlood neoplasia2026

Phase 1B pilot study of itacitinib with alemtuzumab in patients with T-cell prolymphocytic leukemia.

Tapan M Kadia, Akhil Jain, Caitlin R Rausch, Alex Bataller, Farhad Ravandi, Elias Jabbour, Wei Qiao, Gautam Borthakur, Nicholas Short, Guillermo Montalban-Bravo and 6 more

Abstract readClinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Blood neoplasia, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Tapan M KadiaDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX.
Akhil JainDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX.
Caitlin R RauschDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX.
Alex BatallerDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX.
Farhad RavandiDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX.
Elias JabbourDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX.
Wei QiaoDepartment of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX.
Gautam BorthakurDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX.
Nicholas ShortDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX.
Guillermo Montalban-BravoDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX.
Andres E QuesadaDivision of Pathology, Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX.
Jan BurgerDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX.
Alessandra FerrajoliDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX.
William WierdaDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX.
Chitra HosingDepartment of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX.
Hagop KantarjianDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

T-cell prolymphocytic leukemia (T-PLL) is a mature T-cell neoplasm with an aggressive clinical course. Overall prognosis is poor, and treatment relies on alemtuzumab because of inadequate response to conventional chemotherapy. Three-quarters of cases harbor activating mutations in the JAK-STAT pathway (

Identifiers

PMID41536780
PMCPMC12796981

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.